ATC code : N05- PSYCHOLEPTICS Abstract Number : 3PC-006

0

607

STABILITY STUDY OF CLOBAZAM LIQUID ORAL FORMS FOR PEDIATRIC PATIENTS



L.REGNIER¹, A.L.LEROY¹, N.LE POTIER¹, G.JOUAN¹, B.MADIGANT¹, P.N.BOIVIN¹, M.A.LESTER¹ ¹ Pharmacy department, Rennes University Hospital, Rennes, France

BACKGROUND AND IMPORTANCE

Clobazam is a benzodiazepine used as an **anti-epileptic drug** for pediatric patients.

- Several supply difficulties and even stock-outs of the oral suspension specialty for pediatric use.
- This treatment can't be interrupted during a supply disruption and treatment initiations can't be suspended for this indication.

As pediatric doses are weight-adjusted, the development of a liquid formulation was necessary to handle this supply issue.

AIM AND OBJECTIVES

Determine the stability of Clobazam drinkable forms at 2 mg/mL in two different commercial compounding excipients.

MATERIALS AND METHODS

Two formulations of Clobazam 2 mg/mL

Inorpha[®]

Syrspend[®] SF PH4 liquid

Three batches of each formulation:

- packaged in amber glass vials 💹
- at 60% ± 5%

Chemical stability:

- **Measure of pH** (pHenomenal[®] VWR pHmeter)
- **Measure of osmolality** (Advanced Instruments Model 3250[®] Osmometer)
- **Quantification of Clobazam content and detection of degradation products**
 - - - HPLC with UV detection (Λ =210 nm)



Osmolality and pH remained **stable** in both formulations.

Content assessment: \checkmark



At Day 84, the Clobazam concentration of both formulations remained above 95% of the initial concentration. A sedimentation with Inorpha[®] was observed, which explains interdays variability.

No degradation product was observed. \checkmark



CONCLUSION

A Clobazam drinkable forms at 2 mg/mL can therefore be produced in either Syrspend[®] SF PH4 or Inorpha[®] and stored for 84 days at 25°C, protected from light in case of supply shortage. The formulation with Syrspend[®] seems to guarantee a better homogeneity due to viscosity.

